Omeros to Present at the Stifel Healthcare Conference 2013
SEATTLE, Sept. 9, 2013
SEATTLE, Sept.9, 2013 /PRNewswire/ --Omeros Corporation (NASDAQ: OMER), a
biopharmaceutical company committed to discovering, developing and
commercializing products focused on inflammation, bleeding and disorders of
the central nervous system, today announced that Gregory A. Demopulos, M.D.,
chairman and chief executive officer, is scheduled to present at the Stifel
Healthcare Conference 2013 in Boston, Massachusetts this week. The
presentation is scheduled for 2:40 p.m. Eastern time on Thursday, September
The presentation will be webcast. The live and archived webcasts can be
accessed on the "Events" page of the Company's website at www.omeros.com.
About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing products targeting inflammation, coagulopathies
and disorders of the central nervous system. The Company's most clinically
advanced product candidates, OMS302 for lens replacement surgery and OMS103HP
for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform
designed to improve clinical outcomes of patients undergoing a wide range of
surgical and medical procedures. Omeros has six clinical development programs.
Omeros may also have the near-term capability, through its GPCR program, to
add a large number of new drug targets and their corresponding compounds to
the market. Behind its clinical candidates and GPCR platform, Omeros is
building a diverse pipeline of protein and small-molecule preclinical programs
targeting inflammation, coagulopathies and central nervous system disorders.
SOURCE Omeros Corporation
Contact: Jennifer Cook Williams, Cook Williams Communications, Inc., Investor
and Media Relations, 360.668.3701, email@example.com
Press spacebar to pause and continue. Press esc to stop.